Best Haemophilia Treatment Doctors in India

What Patients with Haemophilia Worry About Most

Haemophilia is managed for life, and that long horizon is what families think about first. Parents of newly diagnosed children ask: will my child walk normally, will joint damage develop, is there a cure on the horizon, and how do we manage school and sport. Adults already diagnosed ask whether gene therapy is coming, whether their joints can be repaired, and whether prophylactic treatment is worth the daily commitment. The fear of joint damage from repeated bleeds is the most common long-term concern. Modern factor concentrates, emicizumab prophylaxis, and emerging gene therapy have transformed this outlook for the next generation.

How Haemophilia Is Diagnosed

Haemophilia is confirmed by measuring the factor VIII (in haemophilia A) or factor IX (in haemophilia B) activity level in the blood. Severity is classified as severe (factor level below one percent), moderate (one to five percent), or mild (five to forty percent). The diagnostic workup includes activated partial thromboplastin time (prolonged), prothrombin time (normal), specific factor activity assays, Von Willebrand factor testing (to exclude Von Willebrand disease), and genetic testing. Carrier testing is done for female family members since the inheritance is X-linked. Inhibitor testing (Bethesda assay) is critical because around twenty to thirty percent of severe haemophilia A patients develop inhibitors that neutralise infused factor.

Treatment Options for Haemophilia in India

Treatment has two main approaches: replacement therapy (giving the missing clotting factor) and non-factor therapy (emicizumab). Factor VIII concentrate (for haemophilia A) or factor IX concentrate (for haemophilia B) is the foundation of replacement therapy. Prophylaxis (regular factor infusions two to three times a week) prevents bleeds and joint damage. Extended half-life factor products allow less frequent infusions. Emicizumab is a transformative therapy for haemophilia A. It is a subcutaneous injection given weekly, every two weeks, or every four weeks that mimics the action of factor VIII. For inhibitor patients, bypassing agents (activated prothrombin complex concentrates, recombinant factor VIIa) are used for acute bleeds. Gene therapy (etranacogene dezaparvovec for haemophilia B, valoctocogene roxaparvovec for haemophilia A) is now approved internationally. Dedicated haemophilia clinics at Fortis Memorial Research Institute, Medanta, BLK-Max, Apollo, and Tata Memorial offer the full range of treatment.

Recovery, Outcomes, and Long-Term Care

With modern care, life expectancy is close to normal. The main long-term outcomes are joint health, inhibitor development, and quality of life. Patients on prophylaxis from early childhood often grow up with minimal joint damage and can lead normal lives including most sports. There is no hospital stay for routine care. Patients on factor prophylaxis or emicizumab inject themselves at home. Clinic visits happen every three to six months for clinical review, joint assessment, and inhibitor screening. Acute bleeds are managed with extra factor and sometimes a short hospital admission for major bleeds.

How to Choose the Right Doctor

Look for a doctor with at least ten years of focused haemophilia experience, working at a centre with twenty-four hour factor availability, in-house factor and inhibitor assay capability, and a multidisciplinary team including physiotherapists, orthopaedic surgeons, and dental specialists. Questions to ask: the centre’s approach to prophylaxis, whether emicizumab is available and offered as standard for haemophilia A, the experience with immune tolerance induction for inhibitor patients, and whether gene therapy is being considered or trialled. Centres at Fortis Memorial Research Institute, Medanta, BLK-Max, Apollo, and Tata Memorial have dedicated haemophilia clinics.

Support for International Patients

Treatment in India is more affordable than equivalent care in the United Kingdom, United States, Middle East, or Southeast Asia. Factor concentrates and emicizumab are available at major centres at substantially lower cost than in Western countries. Cancer Rounds arranges the medical visa invitation letter, accommodation, multilingual support in eleven plus languages, and ongoing coordination for long-term factor supply and clinic follow-up. Patients from Nigeria, Bangladesh, Oman, Kuwait, Qatar, Kenya, Uganda, Tanzania, Ghana, Ethiopia, Cameroon, Mauritius, Mozambique, Senegal, Zimbabwe, Zambia, Guinea, Liberia, Madagascar, South Sudan, Qatar, Chad, Sierra Leone, Congo, Iraq & Uzbekistan, and other countries travel to India for haemophilia care every year.

Frequently Asked Questions

Is haemophilia curable?

Until recently, haemophilia was managed but not cured. Gene therapy now approved internationally is offering potential one-time treatment with sustained factor expression. Long-term follow-up will tell whether this represents a true cure.

What is emicizumab and how does it work?

Emicizumab is a bispecific antibody given as a subcutaneous injection weekly, every two weeks, or every four weeks. It mimics the bridging action of factor VIII, so it works in haemophilia A patients with and without inhibitors.

What are inhibitors and how are they treated?

Inhibitors are antibodies the immune system makes against infused factor, neutralising its effect. Acute bleeds are managed with bypassing agents. Immune tolerance induction with daily factor infusions can eradicate inhibitors over months.

Can children with haemophilia play sport?

Yes, most sports are encouraged. Non-contact sports (swimming, cycling, badminton) are particularly safe. Contact sports carry higher bleed risk and are usually avoided. Regular physical activity strengthens muscles around joints.

How do I manage a bleed at home?

For joint or muscle bleeds, infuse factor immediately (within two hours of the first sign), apply ice, compression, and elevation, and rest the joint. For major bleeds (head, abdomen, throat) go to the hospital immediately.

Will my daughter pass haemophilia to her children?

Haemophilia A and B are X-linked, so daughters of haemophilic men are obligate carriers. Each son of a carrier mother has a fifty percent chance of haemophilia. Genetic counselling helps families plan.